Enanta Pharmaceuticals (NASDAQ:ENTA) Given “Buy” Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Enanta Pharmaceuticals (NASDAQ:ENTA) in a research note issued to investors on Tuesday,Benzinga reports. The brokerage currently has a $18.00 price objective on the biotechnology company’s stock. HC Wainwright also issued estimates for Enanta Pharmaceuticals’ Q2 2025 earnings at ($1.42) EPS, Q3 2025 earnings at ($1.81) EPS, Q4 2025 earnings at ($2.00) EPS, FY2025 earnings at ($6.29) EPS, FY2026 earnings at ($9.50) EPS, FY2027 earnings at ($9.80) EPS, FY2028 earnings at ($9.50) EPS and FY2029 earnings at ($8.15) EPS.

Other equities research analysts have also recently issued reports about the company. Robert W. Baird reduced their price target on Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 26th. JMP Securities reaffirmed a “market outperform” rating and issued a $21.00 target price (down from $22.00) on shares of Enanta Pharmaceuticals in a report on Tuesday, November 26th. Two analysts have rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $17.25.

Enanta Pharmaceuticals Stock Up 28.0 %

NASDAQ ENTA opened at $7.50 on Tuesday. The company has a 50-day simple moving average of $5.75 and a two-hundred day simple moving average of $9.51. The firm has a market cap of $159.98 million, a price-to-earnings ratio of -1.37 and a beta of 0.54. Enanta Pharmaceuticals has a 12-month low of $4.71 and a 12-month high of $17.80.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings results on Monday, February 10th. The biotechnology company reported ($1.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative net margin of 171.57% and a negative return on equity of 73.02%. Equities analysts expect that Enanta Pharmaceuticals will post -5.05 earnings per share for the current fiscal year.

Insider Buying and Selling at Enanta Pharmaceuticals

In other news, CEO Jay R. Luly sold 5,142 shares of the company’s stock in a transaction on Friday, December 6th. The stock was sold at an average price of $8.06, for a total value of $41,444.52. Following the completion of the sale, the chief executive officer now directly owns 801,638 shares in the company, valued at $6,461,202.28. This represents a 0.64 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. 13.89% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. bought a new stake in Enanta Pharmaceuticals during the fourth quarter valued at about $26,000. US Bancorp DE lifted its stake in Enanta Pharmaceuticals by 4,933.7% in the 3rd quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 4,243 shares in the last quarter. Intech Investment Management LLC bought a new position in shares of Enanta Pharmaceuticals during the 4th quarter valued at about $58,000. Wells Fargo & Company MN grew its position in shares of Enanta Pharmaceuticals by 69.6% during the fourth quarter. Wells Fargo & Company MN now owns 15,881 shares of the biotechnology company’s stock valued at $91,000 after purchasing an additional 6,518 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Enanta Pharmaceuticals during the 3rd quarter worth approximately $122,000. 94.99% of the stock is owned by hedge funds and other institutional investors.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.